Immunogenetics Unit, Lisbon Centre for Blood and Transplantation (Instituto Português do Sangue e Transplantação, IPST), Lisbon, Portugal.
Immunosurgery Unit, Champalimaud Center for the Unknown, Lisbon, Portugal.
Adv Exp Med Biol. 2020;1273:175-195. doi: 10.1007/978-3-030-49270-0_10.
We review state-of-the-art in translational and clinical studies focusing on the tumor microenvironment (TME) with a focus on tumor-infiltrating B cells (TIBs). The TME is a dynamic matrix of mutations, immune-regulatory networks, and distinct cell-to-cell interactions which collectively impact on disease progress. We discuss relevant findings concerning B cells in pancreatic cancer, the concepts of "bystander" B cells, the role of antigen-specific B cells contributing to augmenting anticancer-directed immune responses, the role of B cells as prognostic markers for response to checkpoint inhibitors (ICBs), and the potential use in adoptive cell tumor-infiltrating lymphocyte (TIL) products.
我们回顾了聚焦于肿瘤微环境(TME)的转化和临床研究的最新进展,重点关注肿瘤浸润 B 细胞(TIBs)。TME 是一个充满突变、免疫调节网络和独特细胞间相互作用的动态基质,这些因素共同影响疾病的进展。我们讨论了与胰腺癌中的 B 细胞相关的研究结果,包括“旁观者”B 细胞的概念,抗原特异性 B 细胞在增强抗癌免疫反应方面的作用,B 细胞作为预测免疫检查点抑制剂(ICBs)治疗反应的标志物的作用,以及在过继性细胞肿瘤浸润淋巴细胞(TIL)产品中的潜在应用。